A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis.

Harrison SA, Bedossa P, Guy CD, et al. N Engl J Med. 2024;390(6):497-509.

Tirzepatide once weekly for the treatment of obesity.

Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022;387(3):205-216.

Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis.

Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Gastroenterology. 2020;159(4):1290-1301.e1295.

Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis.

Loomba R, Hartman ML, Lawitz EJ, et al. N Engl J Med. 2024;391(4):299-310.

The contribution of genetics and epigenetics to MAFLD susceptibility.

Moretti V, Romeo S, Valenti L. Hepatol Int. 2024;18(suppl 2):848-860.

Phase 3 ESSENCE trial: semaglutide in metabolic dysfunction-associated steatohepatitis (MASH)

Newsome PN, Sanyal A, Kliers I, et al. American Association for the Study of Liver Diseases annual meeting. San Diego, California; November 15-29, 2024. Abstract 5018.

Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH/NASH and moderate to noncirrhotic advanced fibrosis.

Noureddin M, Charlton MR, Harrison SA, et al. Clin Gastroenterol Hepatol. 2024:S1542-3565(24)00667-0.

Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.

Noureddin N, Copur-Dahi N, Loomba R. Aliment Pharmacol Ther. 2024;59(suppl 1):S41-S51.

A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

Rinella ME, Lazarus JV, Ratziu V, et al. Hepatology. 2023;78(6):1966-1986.

Is digital pathology the new standard in MASH trials?

Wang Y, Wong VW-S. Hepatology. 2024. [Epub ahead of print]

Once-weekly semaglutide in adults with overweight or obesity.

Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021;384(11):989-1002.